Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

4th year 2nd sem > BIOL 4507- Exam > Flashcards

BIOL 4507- Exam Flashcards

1
Q

translational medicine

A
  • “bench to bedside”
  • a network to connect people working in labs to people working in hospitals
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

describe the chain of people involved in translational medicine

A

PhD trained basic scientists -> MD, PhD trained clinician scientists -> regulatory, legal, and clinical trained specialists -> physicians

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

describe the process of translational medicine

A

human disease -> hypothesis -> funding -> innovation and discovery -> publishing and patenting -> development pipeline (scaling and developing, pre-clinical assessments- animal models, etc.) -> clinical trials -> regulatory approval

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

regenerative medicine

A
  • developing and applying treatments to heal tissues and organs and restore function lost due to aging, disease, damage, or defects
  • encompasses multiple areas of scientific inquiries, each of which is complex, but produce a powerful combination of technologies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

stem cell

A
  • undifferentiated or partially differentiated cells
  • retain the capacity to differentiate into various types of cells (“potency/potential”)
  • can proliferate indefinitely to produce more the same stem cell (clonal expansion)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are the different levels of cells

A

totipotent, pluripotent, multipotent, unipotent, somatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

totipotent

A
  • zygote or morula cells
  • can contribute to all of the cell types of embryonic development, including extra embryonic tissues
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

name the 5 extra embryonic tissues

A
  • placenta
  • yolk sac
  • amnion
  • trophoblast
  • extra embryonic endoderm lineages
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

pluripotent

A
  • have the ability to generate multiple classes of stem cells (e.g. embryonic stem cells can produce mesenchymal, hematopoietic, and neural stem cells) and give rise to all of the cell types that make up the body
  • more restricted than totipotent (can’t produce extra embryonic tissues)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

multipotent

A

have the ability to differentiate into all the cell types within a particular lineage (more restricted)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

unipotent

A

can produce only one cell type but have the property of self renewal that distinguishes them from non stem cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

somatic

A

body cells, can be reprogrammed into pluripotent SC (induced pluripotent SC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are the sources of stem cells

A
  • differentiated somatic cells
  • adult tissues
  • embryonic tissues
  • fetal stem cells
    • originally derived from miscarriages and abortions, restrictions on the use of fetal SC resulted in the development of human induced pluripotent SC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how is stem cell therapy administered

A

ICV transplantation, intravascular infusion, intranasal delivery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Parkinson’s case study

A
  • 70 yr old patient with progressed Parkinson’s (lack of dopamine to coordinate fluid movements)
  • fetal ventral mesencephalon precursor from fetal SC were transplanted into the region of the brain that receives dopamine and gave rise to dopamine producing neurons at maturity
  • patient was able to coordinate fluid movement without medication
  • following research looked into deep brain stimulation due to the difficulty of use and controversy around fetal stem cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

research ethics

A
  • new technological treatments require an ethical backup plan for if the research doesn’t continue progressing
    • support for patients if the technology research does not continue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

molecular organization of cells

A
  • multicellular tissues exist in one of 2 types of cellular arrangements:
    • epithelial
    • mesenchymal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

epithelial cells (4)

A
  • regular columnar morphology
  • cells are relatively static
  • high degree of cell adhesion and cell-cell junctions
  • produce a sheet of cells resting on a basal lamina with an apical surface
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

mesenchymal cells (4)

A
  • irregular, rounded, elongate morphology
  • cells are highly motile
  • bipolar, front-back polarity
  • dynamic adhesions (lamellipoda and filopoda) and held together as a tissue within a 3D extracellular matrix (ECM)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

epithelial sheets (3)

A
  • polarized
  • rest on a basal lamina (ECM that serves as a foundation)
  • can bend to form an epithelial tube or vesicle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

cell junction

A
  • bind epithelial cells robustly to one another and to the basal lamina
  • linker protein attaches to cadherin protein which will attach to another cell’s cadherin protein and link the cells together (dimerization)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

cadherin protein

A

transmembrane protein that spans the entire cell membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

adheren junction

A

initiation and stabilization of cell-cell adhesion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

tight junction

A

continuous intercellular barrier between epithelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

retinal neuroepithelium

A
  • multipotent progenitors are located in the nueroblastic layer (NBL)
  • differentiating neurons and glial cells are located in the inner neuroblatic layer and ganglion cell layer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

glial cell

A

provides physical and chemical support to neurons and maintains their environment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

ganglion cells

A

project info received by the photoreceptors to the brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

vimentin

A
  • intermediate filament expressed in the mesenchymal cells that are differentiating
  • involved in the non-NBL
  • change the shape and polarity of the cell
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

epithelial mesenchymal transition (EMT)

A

rearrangement of cells to create additional morphological features

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

mesenchymal epithelial transition (MET)

A

the reverse process of EMT whereby cells coalesce into an epithelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

conversion of epithelial and mesenchymal cells

A
  • the early embryo is structured as one or more epithelia
  • in the adult organism, EMTs and METs occur during wound healing and tissue remodelling
  • requires the coordinated changes of many distinct families and molecules
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

what are the main mechanisms that stimulate cells to transition into single migrating cells

A
  • changes in cell-cell adhesion
  • changes in cell- ECM adhesion
  • changes in cell polarity and stimulation of motility
  • inversion of the basal lamina
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

changes in cell-cell adhesion

A
  • cells must detach from the epithelium in order to migrate away
  • there are 2 main cadherins that mediate cell adhesion in epithelia:
    • E-cadherin (part of the epithelia layer)
    • N-cadherin (associated with mesenchymal cells, doesn’t dimerize with E cadherin allowing the cells to move)
  • often epithelia will down regulate E cadherin expression at the time of the EMT and express different cadherins, such as N cadherin to promote motility
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

integrin

A
  • transmembrane protein
  • 2 non covalently linked subunits that bind to ECM components (e.g. fibronectin, laminin, collagen)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

changes in cell-ECM adhesion

A
  • clustering of integrins on the cell surface affects the overall strength (avidity) of integrin- ECM interactions
    • more integrins -> increased avidity and stronger ECM interactions
  • different ECM components allow you to manipulate cells differently
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

changes in cell polarity and stimulation of cell motility

A
  • epithelial polarity is characterized by cell-cell junctions:
    • apicolateral domain (non adhesive)
    • basal lamina (adhesive)
  • changes in cell polarity helps promote EMTs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

inversion of basal laminas

A
  • in most EMTs, the emerging mesenchymal cells must penetrate a basal lamina (consists of ECM substrates- collagen type IV, fibronectin, lamina)
  • mesenchymal cells may produce enzymes to degrade and breach the basal lamina (e.g. plasminogen activator)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

how are EMT’s controlled

A
  • transcriptional control (transcription factors)
  • posttranscriptional regulation
  • molecular control (ligand receptor signalling, inflammatory signalling molecules, etc.)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

transcription factors

A
  • regulate gene expression
  • act in concert with one another to create large circuits
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

transcriptome

A
  • a collection of transcription factors that define the cell and what it produces
  • e.g. a stem cell is expressing a certain transcriptome, when it transitions to another type of cell it will express a different transcriptome
  • requires a continuation of signalling that turns on specific profiles of transcription factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

post transcriptional regulation of EMTs (5)

A
  • the activity of EMT transcription factors is regulated at the protein level
    • translational control
    • protein stability (targeting to the proteasome)
    • nucelar localization (in order for things to function in the cell, they have to be in the appropriate location)
    • non coding RNA (silences the ability of a gene to be expressed by binding just before the promoter and preventing transcription of the gene)
    • RNA binding protein
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

musashi- 1

A
  • RNA binding protein (post transcription) expressed in progenitor cells
  • controls genes that define the transition from multipotent to TD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

ligand receptor signalling

A
  • ligands (receptor complexes) interact with target cell receptor and starts a signalling cascade
  • may be diffusible (floating) or expressed on the surface of another cell
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

hierarchical organization of stem cells (3)

A
  • self renewal (can clonal divide to self renew) vs terminally differentiated progeny (exited the cell cycle, no longer dividing, not considered a stem cell)
  • progressive differentiation states
  • vestige status
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

self renewal vs TD progeny

A

symmetrical division and asymmetrical division

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

symmetrical division

A
  • clonal expansion
  • SC -> 2 SC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

asymmetrical division

A
  • can be clonal/TD or TD
  • regulation can be intrinsic (i.e. transcription factors) or extrinsic (e.g. growth factors)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

progressive differentiation states

A

early stem cells, intermediate progenitors, terminally differentiated cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

early stem cells

A
  • long term renewal
  • lots of potential to divide and more likely to be a self renewal potential event
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

intermediate progenitor

A
  • limited renewal
  • more restricted in what it can generate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

terminally differentiated (TD) cells

A

no renewal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

vestige status (4)

A

quiescent, proliferative, intermediate, terminally differentiated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

quiescent

A
  • inactive but ready
  • not in the cell cycle but can reenter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

proliferative

A
  • productive
  • engaged in the cell cycle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

intermediate progenitor (vestige)

A
  • transient (between SC and TD)
  • usually migrating and sometimes dividing
  • lack pluripotency since they are not SC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

terminal differentiated (vestige)

A

cannot divide unless cancerous or reprogrammed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

criteria of pluripotent potential

A

Capacity to differentiate into cells of all 3 germ layers: endoderm, mesoderm, and ectoderm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

how we test for pluripotency

A

stem cells are injected into an immunodeficient mouse and eventually a tumor is produced -> the tumour is removed and examined -> tumors from pluripotent SC will have all three embryonic germ layers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

testing progenitor and SC heterogeneity

A
  • 2 general approaches:
    • transplantation protocols
    • in vitro expansion and differentiation protocols (bulk culturing and single cell colony formation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

bulk culturing

A

the activity of each cell of the population is not reflected by the population average (unable to capture the activity of rare and critical cells and transiently amplifying other cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

single cell colony formation

A

evaluate single cells with a high degree of comprehensiveness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

stem cell sources (6)

A

single blastomere, morula, blastocyst, growth arrested embryo, somatic cell nuclear transfer, parthenogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

morula

A

totipotent SC at the 16 cell stage, the whole clump of cells is taken

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

blastocyst

A

larger mass of cells than a morula (100-200 cells), has a population of different types of pluripotent SC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

growth arrested embryo

A
  • embryos are manipulated to guarantee they are only going to reach a certain stage of development
    • zona pellucida is removed (protection during early development)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

somatic cell nuclear transfer

A

cloning using a donor egg and donor nucleus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

parthenogenesis

A

egg can develop into an embryo without being fertilized with sperm, can result in a lack of genetic diversity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

single blastomere

A

a single cell removed from a blastocyst

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

SC from the amnion (fetal SC)

A
  • from the placenta and fetal membrane (i.e. amnion and chorion)
  • less controversial source of SCs
  • usually discarded after deliver and accessible during pregnancy through amniocentesis and chorionic villus sampling
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

amniocentesis

A
  • prenatal test that take amniotic fluid around the baby in the uterus
  • performed on women at higher risk of delivering a child with birth defects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

sources of FSC

A
  • amniotic epithelial cells (hAEC)- associated with the amniotic fluids/fluid membrane
  • amniotic mesenchymal cells (hAMSC)- associated with the amniotic fluids/fluid membrane
  • chorionic mesenchymal stromal cells- in the chorion
  • chorionic trophoblastic cells- in the chorion
    *all are candidates for use in transplantation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Wharton’s jelly

A

a gelatinous connective tissue, insulates and protects the umbilical cord

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

cord blood stem cells

A
  • unrelated donor source of hematopoietic SC and amniotic epithelial cells
  • accessing these cells allows you to modify them for later treatment
  • previous dark history
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

clinical uses of CB (6)

A
  • transplantation for hematological and non-hematological malignancies
  • inherited metabolic disorders
  • postnatal hypoxic ischemic encephalopathy
  • cerebral palsy
  • stroke
  • autism (inflammatory theory)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

induced pluripotent stem cells

A

introduction of 4 transcription factors can allow any somatic cell to be reprogrammed into an iPSC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

4 transcription factors (yamanaka)

A

oct 4, sox 2, klf4, l-myc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

describe the process of producing iPSC

A
  • retrieve patient’s somatic cells
  • turn on yamanka transcription factors
  • different protocols are used to induce the different tissue types
    *positive feedback loop- transcription factors regulate the expression of a network of pluripotent associated genes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

what are the 4 iPSC reprogramming techniques

A

retroviral transduction, Sendai virus, episomal vectors, introduction of synthetic mRNAs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

retroviral transduction

A
  • retroviruses have the ability to transform their single-stranded RNA genome into a double stranded DNA molecule that stably integrates into the genome of dividing target cells
  • Myc is a proto-oncogene (can mutate into an oncogene)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

sendai virus

A
  • enveloped, single stranded RNA virus
  • replicates directly into the cytoplasm of the host cell without any DNA intermediary
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

sendai virus in iPSC reprogramming (3)

A
  • non integrating (replicates independent of the cell cycle)
  • produces high copy numbers of the target gene (efficient)
  • does not translocate to the nucleus and is diluted with each cell
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

episomal (bacterial) vectors

A
  • non viral and non integrating
  • plasmids are replicated and partitioned into daughter cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

advantages of episomal vectors (2)

A
  • generation of iPSC in a single transfection
  • plasmids are lost over time resulting in transgene free reprogrammed cell lines
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

disadvantages of episomal vectors

A

can sometimes be integrated into the host genome, so the iPSC clones must be subject to genomic analysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

introduction of synthetic messenger RNAs

A
  • mRNA is modified to overexpress pluripotent factors in somatic cells to reprogram them into iPSC
    • substantial number of pluripotent factor expressions needed to drive cell transformation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

disadvantages of the introduction of synthetic mRNA

A

requires repeated transfections to induce over expression of pluripotent protein and further promote reprogramming due to transient (short lasting) expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

epigenetic

A
  • changes in cell function that happen without changes in DNA sequence
  • methylation state of an adult somatic cell must be remodelled during the reprogramming process to unlock access to the pluripotent associated gene network
  • many genes are hypermethylated in donor cell types but hypomethylated in iPSCs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

epigenetic memory

A
  • ability of cells to stably remain and transmit thier unique gene expression patterns to daughter cells
  • epigenetic memories of iPSCs are short term and easily lost; time in culture reduces epigenetic differences among iPSCs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

methylation

A

suppresses gene expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

acetylation

A

encourages gene expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

induced transdifferentiation

A
  • direct transformation from one cell type to another
  • a major mechanism in fish for regrowth
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

advantages of transdifferentiation

A
  • relatively fast in comparison to iPSC
  • less likely than iPSC derivatives to contain residual undifferentiated cells that could produce teratomas
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

disadvantages of transdifferentiation

A
  • mature cell types have a limited capacity to divide
  • require a large input population- cells are not going into the cell cycle, you’re pushing them from one population to another
    • finish the process with less cells than you started with
  • population is clonally derived so genetic manipulation and characterization is difficult/not feasible
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

application of SC

A

disease modelling, personalized medicine, cell therapy, conservation of endangered species

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

disease modelling

A
  • positive results in animal models do not always translate to human studies
    • not surprising since rodents diverged evolutionarily from humans 60 mya
  • iPSCs allow scientists to study human diseases using human cells and dieases for which there is evidence of inheritance but no specific mutations identified
  • iPSCS can be derived from patients with complex diseases that lack a clear genetic basis and preserve their genome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

personalized medicine

A
  • many research methods tend to be similar ethnic backgrounds
    • genetic background of an individual can determine the success or adverse effects of a particular drug
  • can be used to create a customized medical plan or personalized regenerative medicine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

cell therapy

A
  • autologous transplantation of iPSCs and their derivative is expected to be tolerated by the immune system
  • banks of iPSCs that match a large percentage of the population have been created
  • delivery of therapeutic cell types must be targeted to a region of interest
    • IV injection is simple and easy, but often results in the cells being captured by the lungs or liver
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

conservation of endangered species

A
  • endangered organisms can be rederived to increase their population
  • if the population is extinct and you have a cell sample or their genome, you could induce pluripotent SCs and create an embryo to implant into another species
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
99
Q

the hematopoietic system is a self renewal system

A
  • divide and differentiate to produce maturing progeny
  • divide to self renew to maintain a pool of SCs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
100
Q

the site of hematopoiesis changes during development

A
  • placental
  • fetal liver
  • bone marrow (adults)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
101
Q

hematopoietic SC therapies (6)

A
  • bone marrow transplantation
  • autologous/allogenic peripheral blood SC transplantation
  • CB transplantation
  • HSCs for severe combined immunodeficiency
  • HSCs for autoimmune diseases
  • HSCs for tolerance induction post transplant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
102
Q

HSCs for tolerance induction post transplant

A
  • used to prevent the reaction of transplanted organs/cells
  • allogenic cells are mixed with host cells and injected months before the transplant to integrate them into the immune system
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
103
Q

mesenchymal SC sources (6)

A
  • bone marrow compartment (best known source)
  • adipose (accessible)
  • dermal
  • placenta
  • CB and peripheral blood
  • intervertebral disc (remnants of the notochord)
    *high degree of potential
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
104
Q

multipotent adult progenitor cells

A

typically quiescent but possess some primordial potential to recapitulate SC activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
105
Q

types of ASCs

A
  • hematopoietic/immunomodulatory, neural, bone, cardiac
  • certain parts of the organ will have quiescent compartments
  • brain creates new SC for the olfactory area (neurons are exposed and need to be replaced often and for the hippocampus (requrie new neurons for new memories and refreshing memories and synaptic connections))
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
106
Q

biomaterials

A
  • any material, natural or synthetic, that comprises a whole or part of a living structure or biomedical device which performs, amplifies, or replaces the function that has been lost by injury or degenerative condition
  • synthetically and pharmacologically inert
  • used in a variety of sub disciplines (medicine, surgery, dentistry, vet med)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
107
Q

conventional examples of biomaterials

A
  • substitute heart valves (synthetic, xenotranspants)
  • artificial joints
  • dental implants
  • fracture fixes
  • skin regeneration templates
  • contact lens
  • kidney dialyzers
  • blood vessel angioplasty
  • cochlear implants
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
108
Q

3 main classes of biomaterials

A
  • metals (e.g. orthopaedic screws)
  • ceramics (e.g. dental implants)
  • polymers (e.g. drug delivery)
  • can be combined into composites
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
109
Q

properties of biomaterials (6)

A
  • surface properties (rough, coarse, porous, reaction with water)
  • corrosion resistance (electrical signals within the body may be corrosive)
  • innate degradation (material will naturally break down over time)
  • mechanical properties
  • biochemical reactivity (is it going to react with the chemistry around it)
  • radiation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
110
Q

related applications of biomaterials (4)

A
  • implantation (is it inside or outside the body)
  • hemocompatibility (a lot of chemistry occurs in the circulatory system- oxygen carrying capacity, coagulation, etc.)
  • biodegration (body will break down the material- enzymes)
  • immune surveillance (immune system will be reactive towards any foreign material)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
111
Q

applications for biomaterials in regenerative medicine (5)

A
  • cardiopulmonary organ replacements
  • orthopaedic and dental implants
  • surgical sutures and adhesives
  • biological scaffolds
  • nerve regeneration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
112
Q

cardiopulmonary organ replacements

A
  • cardiovascular implants and devices
  • extracorporeal artificial organs
  • artificial erythrocyte substitutes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
113
Q

cardiovascular devices and implants

A
  • artificial heart
  • synthetic heart valves- used for training, potential future use for treatment
  • coronary artery bypass surgery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
114
Q

what do you need to consider when producing synthetic heart valves/vessels

A
  • kinetic energy (heat)
  • stretch
  • diameter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
115
Q

coronary artery bypass surgery (CABG)

A

artery in the heart is blocked, disrupting functioning and rhythm of the heart -> artery is harvested from another part of the body -> donor artery is used to bypass the blocked section

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
116
Q

extracoporeal artificial organs

A
  • provide mass transfer operations to support failing/impaired organ systems
  • e.g. pace maker, insulin pump
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
117
Q

artificial erythrocyte substitutes

A
  • perflurocarbon emulsions (lipid based liquid to contain perflurocarbon)/ microcapsules (more elaborate with a membrane wall)- molecules that can bind O2 (similar to hemoglobin- not good at removing CO2)
  • encapsulated hemoglobin- requires hemoglobin source
118
Q

dental implants

A

retropharyngeal space is linked directly to the pericardium- may introduce bacteria to the rest of the body

119
Q

bone and cartilage implants

A
  • must consider the space between the impact (can facilitate bacterial growth)
  • must consider porosity of the implant (is it rough enough for the bone to adhere to the implant)
120
Q

titanium implants

A
  • titanium is relatively non-reactive, lasts a long time, lightweight
  • technology to detect substances improved (liquid chromatography mass spectrometry)- found that more titanium was leaching from implants than first thought
  • titanium reduces osteogenic differentiation (bone growth), increases peri-implantitis (inflammation around the implant), increases osteoclast differentiation (bone breakdown), and decreases epithelial homeostasis
121
Q

surgical sutures and adhesives (cyanoacrylate)

A
  • accidentally invented by Harry Coover in 1942 (WWII) while he was working on making plastic lenses for firearm optics
  • observed an acrylic resin that rapidly polymerized when reacted with hydrogen and strengthened into a long chain, poly-cyanoacrylate when exposed to water
  • quickly and easily used to close lacerations
122
Q

issues of cyanoacrylate

A
  • curing is exothermic (produces heat) and could cause damage to surrounding tissues
  • curing creates formaldehyde, which irritates skin, eyes, and respiratory systems
123
Q

alternatives to cyanoacrylate

A
  • 2-octyl-cyanoacrylate and n-butyl-2-cyanoacrylate
  • both are improved and less irritating medical adhesives
124
Q

biological scaffolds

A
  • 2d and 3d scaffolds for in vitro growth
  • 3d scaffold for mesenchymal SC tissue growth
  • skeletal and cardiac muscle repair
  • techniques include electrospinning, natural tissues, 3d printing, self assembly, and 3d bioprinting
125
Q

nerve regeneration

A
  • peripheral NS can regenerate nerves relatively proficiently, but not always
  • grafts can be used to bridge nerves together and reestablish connection and function
  • chemotaxis and pathfinding
    • when a neuron is injured and trying to regrow, the pathfinding molecule that it developed surrounded by are no longer present and the cell will likely grow in the wrong location (preferential motor nerve regeneration)
126
Q

bioengineered bridging

A

synthetic material used to bridge the ends of nerves together and facilitate chemotaxis, pathfinding, regrowth, and cell survival mechanisms

127
Q

issues to consider when trialing biomaterials for prosthesis, implants, tissues, and fluids/gels

A
  • biocompatibility- harm, dissolve, get encapsulated, bond with tissue
  • hydrogels-cross linked polymers
  • drug delivery, cell delivery, tamponade, wound healing
128
Q

good manufacturing practice standards

A
  • is the material you’re putting in the body endotoxin (toxin anchored to the cell) free?
  • dalkon shield IUDs
    • composite biomaterial was created, the process of synthesis created endotoxins
    • nylon retrieval string wicked in bacteria
    • resulted in 18 deaths
129
Q

cell-substrate interactions

A
  • ECM, substrates, physical properties
    • crystallinity, morphology, stiffness, compliance
    • surface wet ability, surface charge, cell response
    • can it be engineered/modified
    • is it electrically conductive
    • can its composition be altered
  • cell adhesion, motility, proliferation/differentiation
    • effects of topography and diffusible factor signalling
130
Q

tissue clearing

A

transforms 3d tissue into a 3d nonporous hydrogel-hybridize form that is optically transparent and macromolecule permeable

131
Q

CRISPR

A

clustered regularly interspaced short palindromic repeats

132
Q

describe the origin story of CRISPR

A
  • CRISPRs were first identified in E coli in 1987, when a series of repeated sequences interspaced with spacer sequences was accidently cloned
  • in 1993, JD van Emden discovered that different strains of mycobacteria tuberculosis also had CRISPRs and other genomes were eventually discovered- thought to be a DNA repair mechanism at this point
  • in the early 2000s, Mojica found similar spacer sequences in bacteriophages, viruses, and plasmids
133
Q

CRISPR and adaptive immunity

A
  • viruses cannot infect bacteria harbouring homologous spacer sequences
  • suggests that these sequences play a role in the adaptive immune system in prokaryotes
134
Q

natural mechanism for CRISPR based adaptive immunity

A
  • virus infects a bacteria and inserts its own genome, hijacking the genetic expression mechanism and making all the components needed to reassemble itself
  • if the viral genome is exposed to Cas protein, the cas protein will fragment the spacer sequences of the genome and clone them back into the bacterial genome creating a genetic record of immunization
  • during a subsequent attack, the spacer sequences are transcribed to generate CRISPR RNA which forms an association with a Cas protein. the crRNA will guide the cas to bind to and cleave complementary DNA or RNA viral sequences, munching them up
135
Q

describe the CRISPR-cas system

A
  • CRISPR cas systems can regulate DNA (Cas9) and RNA (cas13)
    • important for viruses, which can be made of DNA or RNA
  • an endonuclease complex- has the ability to bind and cleave DNA
  • requires a guide strand- RNA species that is going to associate with the Cas complex and act as a template to direct it to the target sequence
136
Q

protospacer adjacent motifs (PAM)

A
  • required for the cas complex to cleave DNA
  • expressed on all things other than bacteria - cas cannot cleaves DNA without PAMs- ensures that only foreign viral nucleic acids are cleaved
  • short (2-6 base pairs)
137
Q

can CRISPR be used without PAMs

A
  • no, not at the moment
  • alternative variations on CRISPR editing innovations help add flexibility to this limitation
    • different cas proteins or guide RNA species
138
Q

improving CRISPR

A
  • engineered CRIPSR systems to contain 2 components:
    • CRISPR associated endonuclease
    • synthetic guide RNA (sgRNA/gRNA)- short (20 nucleotides, targets specific regions of the genome
139
Q

site specific endonuclease activity

A
  • endonuclease activity- breaking DNA into 2 fragments
  • the genomic locations that can be targets for editing by CRISPR are limited by the presence of nuclease specific PAM sequences
140
Q

vector

A
  • plasmid DNA ring
  • DNA is continuous with itself
141
Q

blunt end cloning

A
  • insert from a vector is removed and ligase is used to ligate that insert into another vector
  • ends of stand are straight across and may result in inversion
    • the wrong direction is typically non functional
142
Q

sticky end cloning

A
  • insert and vector have overlapping ends (4-6 base pairs)
  • prevents inversion and is more precise
143
Q

restriction enzymes

A
  • recognize specific sequences on the genome
  • might make stick or blunt end cuts
144
Q

non homologous end joining

A
  • DNA is cleaved apart, may result in an insertion, deletion, or frameshift mutation
  • more error prone and less precise
145
Q

homology directed repair

A
  • repair template telling the mechanism what to assemble
  • less error prone and more precise
  • create variations in the template sequence and create whatever mutations you want
146
Q

how is DNA inserted into cells (5)

A

microinjection, balistique gene gun, in vitro/in vivo electroporation, cationic lipids, viruses

147
Q

microinjection

A

teeny, tiny micropipette is used to inject individual cells using electric pulses

148
Q

ballistic gene gun

A

gold particles are coated with the DNA of interest, packed into a bullet, and shot into cells- particles are coat in the cells and the coating is released

149
Q

in vitro/in vivo electroporation

A

opens pores in the cell membrane or envelope allowing the material into the cell

150
Q

cationic lipids

A
  • mini membrane is formed in the presence of DNA/RNA
  • membrane will capture DNA/RNA resulting in a loaded micro particle
  • membrane will integrate efficiently into the target cell’s membrane
151
Q

viruses

A
  • lentivirus- robust and indiscriminate, not worried about the long term outcome of the organism
  • adenovirus- transient gene expression in both dividing and non dividing cells
  • adeno-associated virus (AAV)- transient transgene expression in both dividing and non dividing cells
152
Q

challenges of CRISPR

A

delivery, ethics, off targeting, gene polymorphism in cancer, autoimmune response

153
Q

delivery of CRISPR

A
  • intramuscular
  • systemic (circulatory system)- hitting more organ systems, may be too many (off target effect)
154
Q

phase 1 clinical trial

A
  • evaluates safety, side effects, and best dosage levels
  • 1-2 dozen participants, typically less
155
Q

phase 2 clinical trial

A
  • evaluates safety and efficacy of the treatment (does it actually relieve, reverse, or stop a condition)
  • hundreds of participants
156
Q

phase 3 clinical trial

A
  • evaluates long term adverse effects, how effective the treatment is compared to other standard treatments
  • hundreds to thousands of participants
157
Q

phase 4 clinical trial

A
  • evaluating the safety of the treatment in the broader population, long term risks and benefits
  • thousands of participants
158
Q

CRISPR clinical trials

A
  • trial phases may be combined to expedite testing a treatment
  • all current CRISPR clinical trials target specific cells or tissues in individuals without affecting germ cells
159
Q

CRISPR treatment areas (6)

A

blood disorders, cancer, inherited eye disorders, diabetes, infectious diseases, protein folding disorder

160
Q

blood disorders and CRISPR

A
  • SCD patients have sickle shaped RBCs which clog vessels and cause pain
  • beta thalassemia (BT) patients lack sufficient hemoglobin levels
  • CRISPR can deactivate the gene that prevents the formation of fetal hemoglobin, allowing cells to produce fetal hemoglobin and normal shaped cells
161
Q

cancers and CRISPR

A
  • leukemia and lymphoma
  • Car-T immunotherapy involves genetically modifying a patient’s T cells to have a receptor that allows them to recognize and attack cancer cells
162
Q

car-t immunotherapy trial results

A
  • treatment was safe to administer and had acceptable side effects
  • edited T cells took up residence in the bone marrow and remained at stable levels for the 9 months of the study
  • T cells were able to find and infiltrate tumours
163
Q

off target effects of car-t immunotherapy

A
  • unintended edits at the target site
    • 70% of cells showed at least one mutation at or near the target site during the T cell manufacturing process
  • over time, the percentage of cells with mutations decreased
164
Q

inherited genetic eye diseases and CRISPR

A
  • Leber congenital amaurosis is the most common cause of inherited childhood blindness
  • LCA10 gene is truncated, creating a mutant photoreceptor gene
  • CRISPR replaces short gene with full length gene
  • clinical injection of AAV with photoreceptor tropism- restores gene function
165
Q

diagnostic challenges of LEB CRIPSR treatment

A
  • difficult to evaluate attenuated loss of vision as a positive treatment- how do you tell if someone is getting les blind
  • not restoring vision, just stopping the progression of blindness
166
Q

diabetes and CRISPR

A
  • type 1 is an endocrine disorder that occurs when pancreatic beta cells are destroyed, usually by an autoimmune reaction
  • CRISPR is used to edit the immune related genes of these cells so the patient’s immune system does not attack them
  • edited cells are implanted into the patient’s body in a special pouch and blood vessels grow along the outside of the pouch, bringing oxygen and nutrients and taking up insulin
  • results- only in phase 1, no efficacy data yet, cells need to be isolated to prevent tumour growth
167
Q

infectious diseases and CRISPR

A
  • UTIs
  • cocktail of 3 bacteriophages combined with CRISPR-cas3 designed to attack the genome of the three strains of e coli responsible for 95% of UTIs (destruction of genome kills bacteria)
168
Q

results of CRIPSR UTI treatment

A
  • pending
  • trial supported the safety and tolerability of the new therapy with no drug related adverse effects
169
Q

inflammatory diseases and CRISPR

A
  • hereditary angioedema- patient has severe attacks of inflammation and swelling
  • bradykinin regulates vasodilation (introduces more cells to an area, exacerbating inflammation) and is balanced by c1 inhibitor
  • HAE patients have too much bradykinin, so reducing bradykinin restores the balance of C1: bradykinin
  • results- pending, trial supported the safety and tolerability of the new therapy with no adverse drug effects
170
Q

protein folding disorder and CRISPR

A
  • Hereditary transthyretin amyloidosis (hATTR) is a fatal disease causes by mutations in a single DNA base in the TTR gene
  • mutated TTR gene encodes a misfolded protein that is sticky (amyloid fibrils- clump), and aggregates in organs and tissues
  • results- most adverse effects were midl, all patients showed a reduction in TTR protein levels
171
Q

prion

A
  • pathogenic agents that are transmissible and induce abnormal protein folding
  • prion diseases are fatal degenerative brain disorder
172
Q

mad cow disease

A
  • a progressive neurological disorder of cattle that results from infection by a prion
  • industrial neocannibalism- dead diseased cows are steam treated and refed to cows
    • if you continue reintroducing prions into a cattle community, they will eventually accumulate and cause disease
173
Q

future of gene editing

A
  • “pasting”- inserting DNA to repair or replace harmful DNA
  • multiplex editing- therapy to edit multiple genes at the same time
  • treatment that uses base or prime editing- using CRISPR to directly change single DNA base pairs without making double stranded breaks
  • turning on or off genes without changing DNA sequences
174
Q

bioprinting

A
  • use of printing technology to bioprint tissues and organs
  • aims to achieve reproducible, complex structures that are well vascularized and suitable for future clinical use
  • human tissues and organs have arbitrary 3D shapes composed of multiple cell types and an ECM with functional organization
175
Q

why is vascularization important for bioprinting

A
  • without vascularization, the centre cells of the mass will die (starved of resources) leading to a necrotic core and failed graft
  • must create an environment that is recruiting in vascularization or printing the structure with vascularization
176
Q

computer aided design/manufacturing (CAD/CAM)

A

provides an automated way to replicate the 3D shape of a targeted tissue structure

177
Q

skin perforator flab surgery

A
  • use of healthy autologous donor skin to fix another injured area of the body
  • retains vascularization to ensure the graft doesn’t die
  • historically, cadavers were injected with radio-opaque dye and imaged to determine where perforator flags were located- some error since no one is going to perfectly align with a “generic human”
178
Q

steps to 3D print organs

A

imaging -> modelling and producing bioinks -> bioprinting

179
Q

magnetic resonance imaging (MRI)

A
  • more detail of soft tissues, less detail of bony structures
  • longer duration, higher cost
180
Q

computed tomography (CT)

A
  • less detail than MRI, bony structures are more clear and detailed
  • scan is simple and quick, less expensive
181
Q

sensory arrays

A
  • tell the position of an instrument within the space of the room
  • correlates with imaging
  • combination of modalities are rendered together to form comprehensive imaging
182
Q

bioink

A
  • hydrogels that can encapsulate and deliver cells and bioactive molecules through printing mechanisms
    • cells are collected and cultured to provide the specific cells that you need
  • can be cross-linkable into hydrogels (chemical, physical, enzymatic) before (more shear stress on cells) or after (less clogging, better resolution) printing
  • must consider viscosity
183
Q

3D scanning

A
  • collects 3D data of an object’s shape
  • best for proportionality and dimensions
  • lacks detail that is deep within the structure
184
Q

reverse engineering a 3D scan into a CAD file

A
  • start with interpolating points within and between image slices to improve the resolution
  • generation of voxels (3D pixels) from the measured data
    • extracting localized volumetric data from a targeted tissue structure to generate a surface model
  • point cloud -> voxel model -> wire mesh model (smooth, more accurate surface)
185
Q

mechanisms of bioprinting

A

the effectiveness of each printing mechanism relies heavily on the choice of biomaterials and the targeted applications

186
Q

what are the main components of bioprinters

A
  • 3 axis stage- stage controllers used to move the printer head in the x, y, z directions
  • printing cartridges- usually in the form of a syringe, stores polymeric components of the scaffold or cellular/hydrogel components, contains the nozzle which determines the amount and rate of material dispensed
  • dispenser- deposits the material
187
Q

what are the types of printers used?

A

inkjet, extrusion based, laser assisted, and hybrid

188
Q

inkjet printing

A
  • create a localized temperature/pressure difference that expands material and pushes it down the nozzle
  • includes inkjet and piezoelectric
189
Q

thermal inkjet printing

A

uses an electric heater (200-300C- heat will damage cells; not the preferred method) that generates small bubbles in the printhead, bubbles collapse to create pressure pulses that force droplets of liquid out the nozzle (4-10C rise in hydrogel temp)

190
Q

piezoelectric inkjet printing

A
  • certain materials can generate electric charge in response to applied mechanical stress
  • uses a polycrystalline ceramic to create a pressure pulse that ejects the droplet
  • volume of liquid dispensed depends on temp gradient, frequency of pressure pulse, and ink viscosity
191
Q

extrusion based printing

A
  • additive manufacturing that requires direct contact with a surface to print
  • improved printing resolution, speed, and spatial control
  • material is dispensed in a continuous string and includes the deposition of stacked 2D layers, as opposed to individual droplets
  • may use pneumatic, screw, or piston dispensing
192
Q

pneumatic dispensing extrusion based printing

A
  • uses air pressure to dispense bioink
  • can deposit high viscosity materials
  • delay in deposition owing to the time it takes to compress the gas in the cartridge
193
Q

piston dispensing extrusion based printing

A
  • dispenses bioink with vertical mechanical forces
  • provides more spatial control than pneumatic dispensing but with reduced max force capabilities
194
Q

screw dispensing extrusion based printing

A
  • dispenses bioink with rotational mechanical forces
  • provides more spatial control than pneumatic dispensing but with reduced max force capabilities
195
Q

laser assisted bioprinting

A
  • focused laser pulse fired toward an absorbing layer, typically gold or titanium, to generate high pressure bubbles -> bubbles propel cell-containing bioinks towards a collector substrate
  • have successfully transferred peptides, DNA, and cells
  • nozzle free (avoids clogging), lots of control (increase or decrease laser power to change extrusion drop sizes, frequency, etc.)
  • technology is very robust
196
Q

describe the applications of bioprinting in regenerative medicine

A

3D bioprinted vascular structures
in vitro tissue models

197
Q

three dimensional bioprinted vascular structures

A
  • fully vascularized tissue constructs are required to attain long term cell survival and tissue functions
  • 3D tissue constructs packed with metabolically active cells can rapidly form necrotic cores in the absence of a vascular network
    • promote ingrowth of microvascular system into the implanted bioengineered tissue constructs in a timely manner
    • generate pre-vascularized tissue constructs
198
Q

in vitro models

A

tumor models, drug screening systems, tissue engineering

199
Q

tumor models

A
  • 3D bioprinting of cells as tumour models (can utilize other cell types- liver)
  • tumour models are helpful for studying the interaction of immune and tumour cells for screening new treatments
200
Q

drug screening systems

A
  • a high throughput system that produces a lot of data
  • almost impossible to accurately screen tutor cells and predict the types of drugs that will affect a tumour
  • biopsy tumour cells -> 3D print mini tutors -> place each tumour into a separate well -> high throughput small molecule drug screening program (a family of drugs is introduced to each well, families that affect tumour growth are retested individually to narrow down specific drugs)
201
Q

tissue engineering applications

A
  • bone, cartilage, skeletal muscles and tendons, cardiac tissue and heart valves, skin
  • the 3D printed tissue/device doesn’t necessarily need to resemble the original organ- an artificial lung doesn’t need to look like a lung to be functional
202
Q

bone bioprinting

A

bone graft scaffold that holds cells in the correct size and shape

203
Q

cartilage bioprinting

A
  • 3D printing titanium for personalized joint implants
  • 3D printing cartilaginous features, like noses and ears
204
Q

skeletal muscles and tendons bioprinting

A
  • requires innervation (NS tissue), vascularization, correct order of actin and myosin
  • must be able to generate tendons as well
205
Q

cardiac tissue and heart valves bioprinting

A
  • requires cardiomyocytes, endothelial cells, epicardial cells, fibroblasts
  • each cell type has different characteristics and needs to be treated differently
206
Q

skin bioprinting

A
  • skin grafts create injuries to treat injuries (not ideal)
  • materials that cover a wound and prevent infection have been created, but don’t necessarily function like skin
  • must consider that skin has lots of different layers and components
207
Q

ossicular chain prosthetics

A
  • maleulus, incus, and stapes can be scanned and rendered in 3D
  • allows you to create analogs that have the same functional characteristics and dimensions
208
Q

retinal prosthetics

A
  • retinal implant stimulates sensation of vision, bypassing non functioning photoreceptors
  • optical nerve implant- electrode array is placed around the optic nerve and stimulates the nerve to send info to the brain
  • cortical implant elicits visual perceptions through direct stimulation of the visual part of the brain
209
Q

cell replacement therapy

A

includes transplantation (transplanting into the area it’s going to integrate into) and implantation (uses long distance signalling, may not look like the original thing or be in the original location)

210
Q

experimental workflow of neural cell transplantation

A
  • isolation or engineering or appropriate cell types
  • safe enrichment or expansion of cells to generate sufficient numbers for transplant (cells must be healthy and not releasing toxic chemicals when transplanted)
  • development of surgical delivery protocols (delivery will incur damage, so benefit of treatment must outweigh damage)
  • management of cell viability, motility (you may want cells to migrate or not), integration, and safe functioning throughout the lifetime of the recipient
211
Q

factors to consider for transplantation (8)

A
  • cell preparation and viability
  • storage and handling (storage is very expensive, cells need to be durable enough to transplant and handle)
  • delivery methods
  • surgical placement (deposition shape, deposition cell delivery (how many cells, window of efficacy for cell density), location)
  • immune response
  • donor host interface
  • vascularization
  • are the cells programmed with a virus
    • is the virus active? is everything used in the preparation of GMP? can you kill the transplanted cells if the need arises?
212
Q

autologous

A

cells/tissues obtained from the same individual that it will be transplanted to

213
Q

allogenic

A
  • cells/tissues obtained from a genetically non-identical donor
  • requires donor matching (MHC, rH, blood type)
  • limited in the amount of material that can be harvested
  • immune rejection is huge
214
Q

synergeneic

A

a type of allogeneic transplant in which the donor is an identical twin to the recipient

215
Q

xenogeneic

A
  • cells/tissue obtained from one donor species to be transplanted into a different recipient species
  • immune rejection is huge
216
Q

orthotropic (homotopic)

A

taking cells from a particular location in the donor and putting them in the same location as the recipient

217
Q

ectopic (heterotopic)

A

taking cells from a particular location in the donor and putting them in a different location int he recipient

218
Q

stem cell transplantation therapy workflow

A
  • isolate, enrich, and count cells
  • establish cell viability
  • centrifuge cells to remove storage medium and resuspend in transplant medium
  • final viability count
  • wet ice transplant
219
Q

how are cells counted

A
  • lift adhering cells from the bottom of the dish to get them moving within the slurry
  • 1 micro litre of cells is placed into a hematocrit, dye that only enters dying cells is added, you can then determine the quantity of live cells
220
Q

how are cells resuspended into the transplant medium

A
  • cells are centrifuged -> culture medium is siphoned off and replaced with the transplant medium
  • repeated multiple times- laborious and hazardous
221
Q

SC sources for transplant

A
  • human embryonic SC (derived from the inner cell mass of embryos)
  • adult SC (least controversial, more restricted)
  • fetal SC (ethical controversy)
  • hiPSC (use yamanaka factors)
222
Q

SC transplant slurry composition (6)

A
  • cells need to be delivered in a liquid medium that can support cell viability
    • lots of nutrients- tailored to the cell type you’re transplanting
    • pH and salt buffered
    • endotoxin free
    • albumin (carries hormones, vitamins, and enzymes)
    • hormones (fate (maintain differentiation trajectory), viability (e.g. insulin), inflammation suppressors)
    • temp
223
Q

administration routes of cell transplant therapy

A

intratissue transplantation, intravascular infusion, intranasal delivery

224
Q

intratissue transplantation

A
  • taking a population of cells/chunks of tissue and surgically implanting it into a particular location
  • common
225
Q

intravascular infusion

A
  • systemic injection
  • blood brain barrier is limiting in regards to the CNS
226
Q

intranasal delivery

A
  • brain perforates the skull and has free floating nerve endings in the olfactory epithelium; mucosa traps molecules and delivers them to neurons signalling directly into the brain
  • acts like a super highway into the brain to administer cells
227
Q

delivery methods

A
  • cells are interacting with the glass syringe and needle material
    • cells may stick to the walls of the syringe (syringe can be pre-flushed with bovine serum albumin to coat the glass and prevent adhesion)
    • cells may stick to one another (cohesion)
    • sedimentation of cells may lead to inconsistent dosing
228
Q

stereotactic frame

A

fixed to the patient’s head, provides reference points for targeting

229
Q

factors to consider for surgical delivery of cell replacement therapy (5)

A
  • cell number
  • hub (interface between string and plunger)- bevelled vs right angle
  • cannula thickness (thicker needles have a lower gauge and create more injury but can deliver more cells)
  • needle tip- bevelled (creates and incision and directs cells in a certain direction) vs blunt
  • angle of delivery- changes how the cells sit in the syringe
230
Q

assessment of efficacy post transplant

A
  • assessment is different in animal models vs human models (imaging is more challenging in a living organism)
  • non-invasive in vivo imaging of transplanted cells
  • fire fly luciferase gene + imaging substrate
  • high energy wavelengths are only good for surface imaging; low energy wavelengths are good for deep tissue imaging
231
Q

describe firefly luciferase imaging

A
  • fireflies have a gene that produces luciferase which interacts with a substrate and emits light
  • luciferase can be put into transplanted cells and the substrate can be injected intravenously to cause the cells to glow
232
Q

managing immune response post transplant

A
  • 0-6 hrs after transplant- acute response to surgical al trauma, platelets signal to neutrophils at the transplant site (clotting)
  • 0-3 days after transplant- inflammatory response, complement proteins and platelets signal to neutrophils, neutrophils release cytokines and other responses, if this stage is overactive it will kill everything
  • 3-10 days after transplant- innate response, macrophages and dendritic cells are recruited
  • days to months after transplant- allograft rejection, T-cells recruited
233
Q

transplant medications

A

anti-rejection, anti bacterial, anti-viral, H2 blockers, steroids

234
Q

anti-rejection drugs

A
  • prograf, mycolat
  • lowers the body’s ability to reject the transplant
235
Q

anti-bacterial drugs

A
  • septrin
  • fights bacterial infections
236
Q

anti-viral drugs

A
  • Valcyte
  • treat viral infections by inhibiting the development of viruses
237
Q

h2 blockers

A
  • ranitidine
  • decrease stomach acid produced to protect the stomach from other meds
238
Q

steroids

A
  • prednisone
  • reduce inflammation
239
Q

cellular kill switch

A
  • combination of genetically encoded targets and drug administration
  • targets are sensitive to drug treatment, which activates apoptosis or metabolic gene expression
240
Q

why would you need a cellular kill switch

A
  • transplanted cells may have remnants (certain things integrate into the genome) of reprogramming/processing (hormonal/genetic)
  • safety standards need to be employed to protect the recipient from deregulated donor cell activity
241
Q

pre-clinical applications for cell transplantation

A
  • parkinsons and huntingtons- dopaminergic/glutaminergic cell transplant
  • MS (autoimmune disorder that kills myelination in CNS)- autoimmune cell replacement (cells become myelin or signal existing myeline to stop dying)
  • diabetes- pancreatic islet cell replacement
  • stroke
  • blinding diseases- fetal retinal sheets, photoreceptors, retinal pigmented epithelium
242
Q

what happens when we damage, but not kill, the cells in our body?

A
  • main causes include motorcycle, ATV, and snowmobile accidents and falls from heights
  • we hope that the death cascade (apoptosis/necrosis) doesn’t kill remaining cells
  • we hope that the surrounding microenvironment doesn’t decide to phagocytose stressed cells and take them away (immune response)
  • hope that cells manage to re-establish any unique cell modifications that are required fro function
243
Q

common causes of CNS injuries

A

spinal cord transection, olfactory bulb axotomy, optic nerve transection/ crush injury

244
Q

spinal cord transection

A
  • displacement of the vertebral column that pinches or severs the spinal cord
  • laminectomy (removing part or all of the vertebral bone) is used to attempt to relieve pressure on the spinal cord
    • in some cases there is some restoration to function
    • ## in almost all cases damage is complete and irreversible
245
Q

biotinylated dextran Amin (BDA)

A
  • used as neuron tracers
  • injected into a population of neurons and travels down axons to allow you to visualize where they are or are not travelling to see damage
246
Q

olfactory bulb axotomy

A
  • abrupt impact on the forehead is going to damage the frontal and occipital lobe (brain jolts and hits the front and back of the skull)
  • olfactory nuerons traversing the cribriform plate are going to be sheared
247
Q

optic nerve transection/crush injury

A
  • retinal ganglion cells send their axons to the optic disc and exit the eye forming an optic nerve and becoming a tract in the brain
  • if retinal ganglion cells become acotomjzed, the cells will go through a series of stages of cell death and attempts at regenerating
248
Q

progression of pathological response following optic nerve injury

A
  • mechanical damage -> inflammatory response- first few hours, immune response mediates cell death cascade in CNS and Schwann cells encourage regrowth of axons in CNS (chemokine, cytokines, monocytes, neutrophils, myelination is broken down)-> macrophages and monocytes produce aggressive scarring that prevents regrowth
249
Q

how do neurons develop?

A
  • neurons are born, migrate into a position, and send processes out to places they know they should be making contact
    • if neurons reach out and touch the correct target cell, the target cell will release neurotrophic factors that travel retrogradallly through the axon and signal that it has been hooked up appropriately
    • if neurons reach out and don’t receive neurotrophic factors, the cell dies, ensuring the maintenance of good quality neural circuits
250
Q

target derived trophic support

A

pruning effect used during development to establish the circuitry of the NS

251
Q

growth cone

A
  • swelling at the end of a process of an immature or damaged neuron
  • uses motor proteins and cytoskeletal components to sense molecules in its environment and change shape
252
Q

pathfinding of growth cones during development

A
  • location of the neuron during development determines where they will be located in the brain
    1. neurons sends out axon to find the optic disc
    2. axon fasciculate together to form the optic nerve, which grows into the brain and becomes the optic tract
    3. optic nerve reaches the optic chiasm (decussation point- intersecting nerve fibres that form an X)
    • nasal hemi-retina neuron moves contralaterally, temporal hemiretina moves ipsilaterally
      1. neuron decides whether to fasciculate or de-fasciuclate
      2. neurons decides which region it is targeting
      3. neuron decides which layer to target
253
Q

pathfinding mechanisms

A
  • adhesive substrate bound cues
  • repellent substrate bound cues
  • diffusible chemotropic cues
254
Q

adhesive substrate bound cues

A
  • anchored to a specific region of the pathway
  • tell the axons to stay within certain boundaries
255
Q

repellent substrate bound cues

A
  • tell the growth cone not to go in a particular direction
  • includes slits and ephrins, chondroitin sulphate proteoglycans
256
Q

diffusible chemotropic cues

A

create a concentration gradient that attracts icons and promotes movement in a certain direction

257
Q

regeneration

A
  • regrowth rather than replacement (related to but fundamentally differ from cell replacement therapy
  • can be applied to many organ systems, but the CNS and PNS constitute the prototypical model for tissue regen
  • adult system has changed the enviro to be non-favourable to developmental programs- no guidance molecules or pathways to encourage things
258
Q

general methods for the stimulation of regeneration (4)

A
  • direct drug (biomolecule delivery), cell-based molecular delivery, biomaterials, exploitation of endogenous substrates for regeneration
  • every injury site that is imposed on the NS is going to have a scar that is non-permissive to axons trying to grow through the injury site
259
Q

direct drug (biomolecule delivery)

A
  • done a lot in the early stages of regen
  • dispensing a drug directly to cells to stimulate regrowth and aid in pathfinding for connectivity
260
Q

cell based molecular delivery

A

cell biomaterials that release synthesized factors and encourage cells to regrow

261
Q

biomaterials

A
  • act as scaffolds that display substrate molecules for guidance
  • can be laid out as a conduit and encourage regrowth across the damaged area
262
Q

exploitation of endogenous substrates for regeneration

A

turning on the genes of the original developmental program to promote regrowth

263
Q

regrowing a limb

A
  • the goal of regenerative medicine
  • lower vertebrates are able to regrow completely functional limbs in a short period of time
    • involves the mobilization of a germal zone at the injury site
    • lower vertebrates tend to retain adolescent features (e.g. progenitor cells left over from development that remain dormant until n injury, in which they reawaken and recapitulate what they did in development)
264
Q

slime molds

A
  • innate capacity to explore its enviro and be very selective in decision making
  • mold will send out different processes which probe around in search of food and retract anything that is not proficient
265
Q

oligodendrocytes

A
  • associated with the CNS, can myeline multiple cells (efficient)
  • non-permissive to regeneration- when a cell dies, it releases factors that create a pro-inflammatory response
  • CNS is less likely to be injured than the PNS, thus are less likely to need regen
266
Q

Schwann cells

A
  • associated with the PNS, can only myeline one cell
  • can curb down the inflammatory response and control the type of phagocytic cells coming into the enviro
  • can release trophic factors that encourage the cell to survive and grow
  • can lay themselves out in a line and create a conduit for regrowth
267
Q

preferential motor neural regen

A

nerve successfully regrows, but pathfinding is all messed up and innervates a different structure changing function

268
Q

wound response and barriers to NS regen

A
  • blood brain barrier
  • reactive astrocytes and the glial scar
  • non-growth signalling enviro of the adult NS
269
Q

blood brain barrier

A
  • restricts access of phagocytic elements that can clean up debris
  • restricts the entrance of other cell types that can signal regen
  • breaching the blood brain barrier relieves the restriction of the immune system and inflammatory response allowing for the recruitment of things that shouldn’t be entering
270
Q

reactive astrocytes and the glial scar

A
  • hypertrophy- gets much larger and causes congestion
  • proliferation- start dividing and changing the correct ratio of cells
  • recruitment of microglia- tell microglia to start phagocytizing tissue (inflammatory response)
271
Q

non growth signalling extracellular environment of the adult NS

A

system doesn’t have the correct cues to grow into the correct pathways

272
Q

primary injury

A
  • damage to the tissue
  • includes uncontrolled necrotic death, inflammation, ischemia (lack of blood flow), and hypoxia (lack of O2)
  • processes persist for weeks and initiates a second wave of death
273
Q

secondary injury

A
  • continued loss of tissue due to cascade of molecular and genetic changes post-primary injury
  • includes apoptosis (neurons and oligodendrocytes), increase in injured tissue volume, formation of spindle shaped cystic cavity, insolation of injured tissue from the tissue environment by reactive astrocytes through the formation of a glial scar
  • often described as a sequelae (consequence of a previous disease or injury)
274
Q

injury timeline

A
  • injury event- primary injury
  • intermediate- second to minutes, hemorrhage, decrease in ATP, increase in lactate (acidosis)
  • early acute- minutes to hours, vasogenic and cytotoxic edema, micro vessel vasospasm, thrombosis, ion imbalance, loss of Na gradient, release of neurotic opioids, inflammation, lipid perioxidation, glutamatergix excitoxicity, formation of free radicals
  • sub-acute- days to weeks, micoglial stimulation, macrophage activation, apoptosis
275
Q

clinical response to injury

A
  • administration of steroids and anti-oxidant drugs
  • release of any compression via surgery
  • management of inflammatory response
  • rehabilitation
276
Q

mechanisms of neurite growth

A
  • filopodia and lamellipodia are mediated by motor molecules, actin, and cytoskeletal components
    • different zones of signalling and extension/retraction allow for the growth cone’s dynamic nature
277
Q

describe growth cone motility (5)

A
  • mediated by actin polymerization and myosin contraction
    • up and down regulation of each pathway allows for dynamic movement
  • cytoskeletal component allows the growth cone to grow and navigate the enviro
  • microtubule binding protein can stretch/coil and signal cascade of molecular response (senses contraction/extension)
  • chemoattractant molecules guide the growth cone
  • cell adhesion molecules allow the growth cone to move through the enviro
    • filopodia molecularly couple and uncouple with cell adhesion molecules to pull itself forward and probe the enviro
278
Q

regenerative sprouting

A

occurs when the axons innervating a structure are severed and a growth cone is formed and regenerates new axons- more sprouting leads to more success

279
Q

zebrafish and spinal cord regen

A
  • lower vertebrates face the same problems in regen as humans, but efficiently resolve them
  • in mammals, nerve injuries result in a necrotic core that won’t go away; zebrafish have the same cells, but they interact differently
    • ependymo-radial glial cells (ERG) can efficiently create a pathway that cells can regrow through
      • ERG cells are used during development in humans but are lost by adulthood p
    • cell substrates remain a part of the CNS and mediate regenerating axons, remove the inflammatory response, and remove activated glial cells, allowing for regrowth
280
Q

biomolecule delivery and guidance conduits using biomaterials

A
  • biomaterials allow you to choose viscosity, release molecules at a predictable rate, encourage cells to survive and regrow, etc.
  • conduits/tubes allow axons to grow through or around an injury
281
Q

olfactory ensheathing cells

A
  • peripheral cells that can replace the functioning of the Schwann cells and are very accessible
  • protect the axons as they go through the cribriform plate
  • robust, in constant contact with the external enviro- good at regenerating themselves
282
Q

transplanting olfactory ensheathing cells

A
  • can be transplanted into many areas of the CNS and effectively encourage regrowth
  • work like Schwann cells
  • suppress the immune and inflammatory response, reduce fibrotic scarring, and create a substrate that provides a conduit for regrowth
283
Q

philipe monnier

A

rewrote a lot of the molecular signalling mechanisms that mediate the regrowth process

284
Q

repulsive guidance molecule

A
  • released within the enviro
  • signal the growth cone to collapse and regulate gene expression and neurite outgrowth and attraction
  • allows you to direct regrowth and regeneration within the CNS
  • clinical trials looking at variations of RGMs to direct regrowth in the context of stroke and traumatic brain injuries
285
Q

pre-context to xenobots

A
  • all somatic cells contain the same genome; what creates variability in cell gene function is which genes are expressed and when
  • germ cells are embedded within a population of other cells that are constantly communicating and secreting molecules that instruct them what to do
    • all of the cells are responding tot he genetic programming of the genome, but deploying the communication in a very specific way
  • what happens if you take the cells out of the enviro and let them behave how they want to?
286
Q

synthesis of xenobots (6)

A
  1. supercomputer modelling
  2. SC collection, dissociation, and agitation
  3. pushing the fate of the SC into something that doesn’t look like the original body plan
  4. biobanking (storage)
  5. assembly
  6. shaping and using microsurgical tools (based on the computer modelling)
287
Q

applications of xenobots

A
  • delivery of therapeutics
  • direct repair of damaged tissue
  • attack diseases
288
Q

characteristics of xenobots (6)

A
  • programmable living beings
  • communicate with each other
  • can create other xenobots
  • can change their cell expression
  • create cilia (movement- can navigate their enviro)
  • self healing
289
Q
A
290
Q
A
291
Q
A

4th year 2nd sem (6 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions